Sign In
Buy CNCE
$8.37
+0 (+0%)
At Close: May 30, 2023
Concert Pharmaceuticals, Inc. (CNCE) Q3 2022 Earnings Call Transcript
09:58am, Monday, 07'th Nov 2022
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE ) Q3 2022 Earnings Conference Call November 7, 2022 8:30 AM ET Company Participants Justine Koenigsberg - Senior Vice President, Corporate Communications and
Concert Pharmaceuticals (CNCE) Reports Q3 Loss, Misses Revenue Estimates
09:50am, Monday, 07'th Nov 2022
Concert (CNCE) delivered earnings and revenue surprises of 1.69% and 97.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Concert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022
07:00am, Monday, 31'st Oct 2022
LEXINGTON, Mass.
Recent Price Trend in Concert (CNCE) is Your Friend, Here's Why
10:32am, Wednesday, 07'th Sep 2022
If you are looking for stocks that are well positioned to maintain their recent uptrend, Concert (CNCE) could be a great choice. It is one of the several stocks that passed through our "Recent Price S
Wall Street Analysts Think Concert (CNCE) Could Surge 127%: Read This Before Placing a Bet
11:17am, Monday, 22'nd Aug 2022
The average of price targets set by Wall Street analysts indicates a potential upside of 126.6% in Concert (CNCE). While the effectiveness of this highly sought-after metric is questionable, the posit
Recent Price Trend in Concert (CNCE) is Your Friend, Here's Why
10:33am, Monday, 22'nd Aug 2022
Concert (CNCE) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our sh
Here's Why Concert Pharmaceuticals (CNCE) is a Great Momentum Stock to Buy
01:33pm, Tuesday, 16'th Aug 2022
Does Concert Pharmaceuticals (CNCE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q2 2022 Results - Earnings Call Transcript
10:50am, Saturday, 06'th Aug 2022
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Justine Koenigsberg - Senior Vice President, Investor Relations Roger Tung
What Makes Concert (CNCE) a Good Fit for "Trend Investing"
10:32am, Friday, 05'th Aug 2022
If you are looking for stocks that are well positioned to maintain their recent uptrend, Concert (CNCE) could be a great choice. It is one of the several stocks that passed through our "Recent Price S
Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Lags Revenue Estimates
10:32am, Thursday, 04'th Aug 2022
Concert (CNCE) delivered earnings and revenue surprises of 34.44% and 93.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Concert Pharmaceuticals to Report Second Quarter 2022 Results on August 4, 2022
07:00am, Friday, 29'th Jul 2022
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert will report its financial results for the second quarter of 2022, on Thursday, August 4, 2022.
Concert Pharmaceuticals: A Balanced Risk/Reward
11:48am, Wednesday, 15'th Jun 2022
Concert Pharmaceuticals has a JAK inhibitor for alopecia areata (AA) that may be superior to competitive products. The company cites a figure of 1.5m US patients with AA. Published literature cites a
What's Going On With CCL Industries Shares Today
02:02pm, Friday, 13'th May 2022
RBC Capital analyst Walter Spracklin lowered the price target for CCL Industries Inc (TSX: CCL.B) (OTC: CCDBF) to C$74 from C$80. The analyst maintained the Outperform rating on the shares.
Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q1 2022 Results - Earnings Call Transcript
01:56pm, Saturday, 07'th May 2022
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE ) Q1 2022 Results Conference Call May 5, 2022 8:30 AM ET Company Participants Justine Koenigsberg - Senior Vice President, Investor Relations Roger Tung - Ch
Earnings Preview: Concert Pharmaceuticals (CNCE) Q1 Earnings Expected to Decline
04:34pm, Tuesday, 26'th Apr 2022
Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
